Reinhard Dummer, MD, PhD, University Hospital Zürich, Zürich, Switzerland, discusses the role of targeted therapies in the treatment of melanoma. Different combinations are discussed including vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib for metastatic melanoma. Combinations with target molecules present clear benefits in progression-free survival (PFS). However, PFS can still be improved further. Prof. Dummer suggests the evaluation of immune checkpoint inhibitors, such as ipilimumab and nivolumab, which have been shown to improve PFS in combination with other drugs. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.